Tissue Regenix (GB:TRX) has released an update.
Tissue Regenix Group PLC reports a 16% increase in revenues to $16.4 million in H1 2024, with significant growth in their regenerative medical devices driven by BioRinse and dCELL technology platforms. The company has doubled its adjusted EBITDA profit to $1.1 million and maintained a solid cash position, while achieving its eighth consecutive period of growth. The successful results are attributed to strategic growth initiatives, including the expansion of its San Antonio facility, expected to complete in 2025.
For further insights into GB:TRX stock, check out TipRanks’ Stock Analysis page.
